T-cell agonists in cancer immunotherapy

Area of Science:

• Immunology
• Oncology
• Pharmacology

Background:

• Cancer cells evade immune surveillance, hindering T-cell responses.
• Immune checkpoint inhibitors (ICIs) block inhibitory signals, restoring T-cell activity.
• Costimulatory molecules (e.g., 4-1BB, OX40, ICOS, GITR, CD40) are crucial for T-cell activation and function.

Purpose of the Study:

• To review current knowledge on T-cell agonists in cancer immunotherapy.
• To summarize findings from recent and ongoing clinical trials of T-cell agonists.
• To explore combinations of T-cell agonists with other cancer therapies.

Main Methods:

• Review of preclinical data and clinical trial outcomes for T-cell agonists.
• Analysis of studies involving agonists targeting 4-1BB, OX40, ICOS, GITR, and CD40.
• Examination of combination therapies including ICIs, radiotherapy, and chemotherapy.

Main Results:

• Agonists of costimulatory molecules show promising preclinical and early-phase clinical results.
• Ongoing clinical trials are evaluating these agents in various advanced cancer settings.
• Combination strategies with ICIs and other treatments are under active investigation.

Conclusions:

• T-cell agonists represent a significant advancement in cancer immunotherapy.
• Further clinical trials are essential to establish the efficacy and safety of these agents.
• Combination therapies hold potential for improving treatment outcomes in advanced cancers.